Influencing TB control policy and practice in Nepal & Pakistan
Submitting Institution
University of LeedsUnit of Assessment
Public Health, Health Services and Primary CareSummary Impact Type
PoliticalResearch Subject Area(s)
Medical and Health Sciences: Public Health and Health Services
Summary of the impact
Leeds research has led to adoption of effective, patient-friendly
tuberculosis (TB) care delivery in
Nepal and Pakistan, relaxing the global TB treatment strategy's
requirement that (generally very
poor) patients attend a health centre every day for 2 months for
supervision and support that led to
unemployment, poverty and debt. This impact has reach across the more than
300,000 people a
year treated for TB in Nepal and Pakistan; and its significance is that
patients can retain their usual
employment yet still have a high likelihood of cure. Our research
demonstrated that home-based
care was feasible under routine low-income country TB programme
conditions, was as effective as
health centre-based care, and was much more acceptable than health
centre-based care.
Underpinning research
TB is a major global cause of illness and death: the World Health
Organisation (WHO) reports that
in 2011, 8.7 million people fell ill with TB, and 1.4 million people died
from TB; and over 95% of TB
deaths occur in low- and middle-income countries. Until 2006, the TB
control policy recommended
by WHO included Direct Observation of Treatment (DOT) by a health worker
at a health centre
daily for at least the first 2 months of treatment. We observed that this
strategy caused substantial
hardship to poor patients, severely disrupting their ability to work,
since health centres are
generally only open during working hours. During treatment, many employed
TB patients lost their
jobs; daily labourers could not get work; farmers struggled to access
clinics; household duties
including childcare were disrupted; and school and college students had
difficulties continuing their
studies. Health centre DOT ignores the imperatives of daily survival for
poor people, and forces
many people to seek care in the private sector, which has poor treatment
outcomes, leading to
further illness and death, and continuing transmission of TB.
Despite being part of global policy, there was no evidence to support the
use of health centre DOT
rather than more flexible ways of encouraging continuation and completion
of treatment. We
hypothesised that flexible strategies could produce cure rates as good as
or better than daily
health centre DOT and be more patient-friendly. We planned from the outset
that if the context-
appropriate strategies we developed proved effective, we would use our
good relationships with
National TB Programmes to encourage changes in policy and help implement
such strategies.
From 1996 to 2000, our research team at the University of Leeds carried
out an individually
randomised controlled trial in Pakistan to compare treatment outcomes and
patient satisfaction
using daily health centre DOT with those obtained using more
patient-friendly strategies of
treatment supervision and patient support by community health volunteers
or family members at or
near the patient's home. The team was led by John Walley
(Professor of International Public
Health, employed by UoL 1992-) with James Newell (Professor of
International Public Health,
1995-) and Amir Khan (UoL PhD graduate, who set up a Pakistani NGO - the
Association for
Social Development - to operationalize the research and development).
The trial demonstrated that patient-friendly approaches led to higher
cure rates than daily health
worker DOT (1). Our development of these approaches was guided by a
social science study
identifying constraints to TB control from patients' and providers'
perspectives (2); and we also
carried out a study demonstrating the cost-effectiveness of the approaches
(3).
We then carried out the first cluster-randomised controlled trial to
investigate the impact of patient-
friendly strategies for treatment supervision and patient support. The
trial randomised districts in
hill and mountain areas of Nepal, where standard daily health centre DOT
was clearly not feasible
because of the unavailability of accessible clinics. This trial
demonstrated that under normal health
service conditions, patient supervision at home by a family member or by a
community health
volunteer achieved cure rates of 89% and 85% respectively (4),
higher than the international target
of 85%; and patient satisfaction was high. A subsequent costing analysis
demonstrated that the
costs of the two strategies were similar, and affordable to the Nepal NTP
(5). The research team
was led by James Newell and included Sushil Baral (UoL PhD
graduate, who set up a Nepali
NGO - the Health Research and Development Forum - to operationalize the
research and
development); Tolib Mirzoev (Senior Lecturer, 2004-) and Andrew
Green (Professor of
International Health Planning, 1983-2004).
Our contribution to the field of study was that, at the time, although
there had been a small number
of studies comparing DOT to non-DOT (unsupervised self-administered) TB
care, our studies were
the only ones comparing different DOT strategies and demonstrating their
effectiveness.
References to the research
[University of Leeds staff at the time of the research in bold]
1. Walley JD, Khan MA, Newell JN, Khan MH (2001).
Effectiveness of the direct observation
component of DOTS for tuberculosis: a randomised controlled trial in
Pakistan. Lancet, 357,
664-669. doi:10.1016/S0140-6736(00)04129-5. Cited 110 times.
Results from the first trial to show that more patient-friendly
approaches to DOT are effective.
2. Khan MA, Walley J, Newell J, Imdad N (2000).
Tuberculosis in Pakistan: socio-cultural
constraints and opportunities in treatment. Social Science and Medicine,
50, 247-254.
doi: 10.1016/S0277-9536(99)00279-8.
Identification of problems of daily health centre DOT from
patient/health provider perspectives.
3. Khan MA, Walley JD, Witter SN, Imran A, Safdar N
(2002). Costs and cost effectiveness of
different DOT strategies for the treatment of tuberculosis in Pakistan.
Health Policy and
Planning 17(2), 178-186. doi: 10.1093/heapol/17.2.178.
Analysis of the trial (1) showing that the patient-friendly DOT
strategies we developed are
more cost effective than daily health centre DOT.
4. Newell JN, Baral SC, Pande SB, Bam DS, Malla P
(2006). Family member DOTS and
community DOTS for TB control in Nepal: district randomised trial. Lancet,
367 (9514), 903-
909. doi:10.1016/S0140-6736(06)68380-3.
Results from a large cluster-randomised trial showing effectiveness of
our strategies within
usual health service care.
5. Mirzoev T, Baral SC, Karki D, Green AT, Newell
JN (2008). Community-based DOTS and
family member DOTS for TB control in Nepal: costs and cost-effectiveness.
Cost Effectiveness
and Resource Allocation 2008, 6:20. doi:10.1186/1478-7547-6-20
Analysis showing the two approaches tested in Nepal (4) were affordable
and comparable.
Grant support (open competition peer-reviewed grants)
Walley - TB DOT project trial in Pakistan (DFID 1995-98 £313,824); Newell
- TB service delivery
in areas with poor access to health facilities in Nepal (DFID 2000-3
£247,094).
Details of the impact
Our work has directly led to changes to government policy and public
service guidelines and
practices for TB control across Nepal and Pakistan, improving care for
more than 300,000 people
with TB annually, and helping to protect nearly 200 million people from TB
annually. The strategies
we developed and demonstrated were effective, which have been rolled out
since 2008, have led
to improved quality of life for patients through reduced financial burden,
better treatment outcomes,
reducing risk of TB spread and development of drug resistant strains of
TB. Without our research,
and development support, it is unlikely that any change to care would have
occurred. These
strategies have also been adopted in other low-income countries, such as
Swaziland.
Impacts on international development
From the outset, to ensure our research influenced policy and practice at
large scale, we adopted
a deliberate strategy of working closely with National TB Programmes. This
strategy develops
trust; ensures our research addresses national priorities; ensures
findings are relevant for policy
makers; promotes policy-makers' ownership of the research findings; and
encourages joint
development of subsequent policy, operational guidelines and training
methods and materials.
Much of our research uptake was made possible through our partnership with
in-country research
and development NGOs, set up by ex-students/employees of the University of
Leeds. TB
Programme Managers and members of their teams were involved from
conception (responding to
their prioritisation of the problems) to completion. This included joint
development of the
interventions to be tested, regular briefings and discussions of likely
implications of findings.
Our research and research uptake strategy have together led directly to
better, evidence-informed,
public policy and improved public services in Nepal and Pakistan for
people with TB. We were
involved in the development of draft national policy and operational plans
published since 2008.
National guidelines adopted since 2008 have been revised to take account
of our findings, and our
patient-friendly approaches have been implemented in both in Nepal (A-G)
and Pakistan (H-J).
We have also jointly developed training materials and courses that have
been used by the TB
Programmes from 2008 onwards to train health workers in the new
strategies. Walley and Newell
have provided on-going advice and support to the NTPs throughout the
assessment period.
More widely, the research influenced key WHO/Stop TB Partnership (www.stopTB.org)
documents
(K-M) (including the Stop TB strategy 2006), in which the
requirement for DOT has been replaced
by a more patient-centred approach of `supervision and patient support'.
Although publication of
these documents falls outside the assessment period, their influence in
encouraging adoption of
this strategy across low-income countries has continued throughout the
assessment period.
Impacts on health and welfare
Our research and our research uptake strategy have together led to 100%
reach across our
intended target populations - the (overwhelmingly poor) people of
Nepal and Pakistan receiving
care for TB - starting in 2008 and continuing to date. This means improved
care for 30,000 people
with TB in the mountain/hill districts of Nepal annually, helping protect
30 million people from TB
infection in Nepal (A-G); and improved care for 300,000 people with
TB in Pakistan annually,
helping protect 177 million people in Pakistan (H-J) (based on WHO
statistics on numbers at risk).
Our research has also contributed to improved TB treatment outcomes in
both countries (N).
- in Nepal, the TB treatment success rate was 48% (case detection 56%)
in 1995 prior to our
research, and 85% (case detection 71%) in 2011: mortality fell by 900 to
7,000.
- in Pakistan, the TB treatment success rate was 70% (case detection
4.5%) in 1995, and 91%
(case detection 65%) in 2011: mortality fell by 31,000 to 59,000.
Our research has also led to significantly improved quality of life
for people with TB in Nepal and
Pakistan, who no longer need to attend a clinic daily, and can therefore
continue their usual
employment/duties and follow normal lives (4), reducing the burden
and costs of TB.
- In Nepal, we estimated costs to patients using family/community health
worker DOT were
US$32 lower than using standard health centre DOT (a reduction of nearly
50%) (5). To put this
in context, the average annual income (2001) was US$400 and 55% of the
population earned
less than the international poverty line (IPL) of US$1.25 per day.
- in Pakistan, we estimated costs to patients using family/community
health worker DOT were
US$27 lower than using standard health centre DOT (a reduction of 50%) (3).
The average
annual income (2001) was US$750 and 23% of the population earned less
than the IPL.
Sources to corroborate the impact
Key external outputs
Nepal Ministry of Health and Population (2010). National
Strategic Plan - Implementation of
Stop TB Strategy 2067/68-2071/71 (16 July 2010-15 July 2015). Kathmandu:
National
Tuberculosis Centre. (See section 2.9, p50, and acknowledgement on page
16.) Available at
www.nepalccm.org/resources/tuberculosis/pdf/nationalstrategicplan2010-15.pdf
Nepal Ministry of Health and Population (2012). Nepal NTP
General Manual 3rd edition. (See
pages 4, 9, 10, 31 for role of family members in TB patient support.)
Available at
http://nepalntp.gov.np/theme/images/uploads/1373865242eneral_Manual_en.pdf
C. Nepal Ministry of Health and Population (2009). Tuberculosis
Case Management Guideline 1st
edition. (Also in Nepali.) (See page 18 for role of family members in TB
patient support.)
http://library.elibrary-mohp.gov.np/mohp/collect/mohpcoll/archives/mohp:204/9.dir/doc.pdf
D. Annual Report 2008/09, Ministry of Health and Population,
National Tuberculosis Programme,
Nepal. Available at http://www.docstoc.com/docs/140273075/Department-of-Health-Services---
Ministry-of-Health-and-Population
E. Annual Report 2008/09, Ministry of Health and Population,
National Tuberculosis Programme,
Nepal. (See pages 2, 9 for role of family members in TB patient support;
and
acknowledgement on page 32.) Available at
http://nepalntp.gov.np/theme/images/uploads/1359021203l_Report_NTP_2011.pdf
F. The current Chief of the Policy Planning and International
Cooperation Division of the Nepal
Ministry of Health and Population can confirm the impact of our research
on TB service
delivery in Nepal.
G. The Deputy Director of the Nepal National Tuberculosis
Programme during the period when
our findings were incorporated into Nepal national policy can confirm the
influence of our
research on national health policy in Nepal.
H. National TB Control Programme Pakistan (2008). Desk guide for
doctors. (See pp8-9 for role
of family members and community health workers in TB patient support; p20
for
acknowledgement of input from Nuffield Institute for Health, University of
Leeds.)
I. National TB Control Programme, Ministry of Health, Government
of Pakistan (2008). Refresher
module for doctors. (See p18 for role of community health workers in TB
patient support.)
http://ntp.gov.pk/uploads/ntp_1369816170_Doctor_Module_Nov_2008.pdf
J. Letter from the Programme Manager of the Pakistan National TB
Programme during the period
when our findings were incorporated into Pakistan national policy
confirming the impact of our
research on national health policy in Pakistan.
K. The Stop TB Strategy. WHO and the Stop TB Partnership 2006 (WHO
document number
WHO/HTM/STB/2006.37). (See p2 for acknowledgement of input from John
Walley.)
http://www.who.int/tb/strategy/en/
L. The Global Plan to Stop TB 2011-2015. WHO and the Stop TB
Partnership (WHO document
number WHO/HTM/STB/2006.35). (See p7 for acknowledgement of input from
James Newell.)
http://www.stoptb.org/global/plan/
M. An Expanded DOTS Framework for Effective Tuberculosis Control.
WHO (WHO document
number WHO/CDS/TB/2002.297). (See p2 for acknowledgement of input from
John Walley.)
http://www.who.int/tb/publications/expanded_dots_framework/en/
N. Global Tuberculosis Control: WHO Report 2012. (WHO document
WHO/HTM/TB/2012.6).
http://www.who.int/tb/publications/global_report/en/
All manuals, guidelines and training materials listed above have been
developed by the national
bodies responsible in the relevant countries (National Tuberculosis
Control Programmes, etc).
(NB WHO rules prohibit staff from providing letters of support that could
be perceived as favouring
any individual or establishment.)